<DOC>
	<DOC>NCT01268787</DOC>
	<brief_summary>This study is aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine at a 0.25ml or 0.5ml dose in health volunteers</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine</brief_title>
	<detailed_description>This is a phase I, prospective, randomized, open-label, two-center study. A total 60 healthy volunteers will be screened for baseline characteristic inclusion/exclusion criteria after providing a written informed consent. Eligible subjects will be recruited and equally randomized to either receive 2 doses of EV71 vaccine 0.25ml or 0.5ml. All subjects should be followed till Day 210.</detailed_description>
	<mesh_term>Enterovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject who is free of obvious health problems Able and willing to comply with the study procedure adn give written informed consent Female who is pregnant/lactating or planning to be pregnant Body mass index(BMI) &gt; 35 Oral temperature &gt; 37.5 Celsius at the time of planned vaccination Subject with any abnormal laboratory results at screening With a history of herpangina, handfootmouth disease, acute hemorrhagic conjunctivitis or acute gastrointestinal illness associated with enterovirus infection in the past 3 months Has been diagnosed with neurological, pulmonary, cardiovascular, hematological, hepatic or renal disorder With a history of hypersensitivity to vaccine or allergic disease Use of any investigational/nonregistered product within 30 days prior to vaccination Use of immunoglobulins or any blood products within 3 months prior to vaccination Chronic administration of immunosuppressants or other immunomodulators within 5 months prior to vaccination</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>